The Research Digest is a weekly, dated watch of new peer-reviewed peptide studies, analytical and manufacturing developments, standards updates and regulatory notices. Each entry summarises what was published, in what model, and what it does and does not establish, with a link to the primary source.
In this digest
HHS issues a 503A enforcement-discretion notice for six peptide bulk drug substances
RegulatoryOn October 28, 2026, the Office of the Secretary of the U.S. Department of Health and Human Services filed for public inspection a notice of availability titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances” (Docket No. HHS-OASH-2026-0496), published in the Federal Register on October 30, 2026. The policy states that, until each substance is addressed in a final rule on the section 503A bulk drug substances list, HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician compounding with a bulk drug substance listed in its Appendix A. Appendix A names six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.
Several of its numbered conditions concern analytical quality. The bulk substance must come from an establishment registered under section 510, with the facility’s physical location listed on the certificate of analysis, and the COA must report the testing specified in Appendix B, including orthogonal methods and endotoxin, microbial and residual-solvent results. Appendix B also records that FDA’s Center for Drug Evaluation and Research recommended against listing each substance, and that the Pharmacy Compounding Advisory Committee voted in favour.
What this does and does not establish. The notice is an interim, non-binding statement of enforcement intent; the Federal Register text describes it as a draft policy in several places. It does not add any peptide to the 503A bulks list and does not approve any drug, and the document itself states that compounded drugs are not FDA-approved and that FDA does not review their safety, effectiveness or quality before they are marketed. HHS states that it may revisit the policy if a safety or quality issue arises. Its scope is limited to 503A compounding by the entities it names.
Source: U.S. Department of Health and Human Services, Office of the Secretary. Notice of availability, FR Doc. 2026-22192; filed October 28, 2026, published October 30, 2026. public-inspection.federalregister.gov/2026-22192.pdf; policy text: hhs.gov policy PDF.
Related guide: How to Read a Peptide COA
MS Andrea: an open-modification search that resolves combined peptide modifications
MethodsOpen-modification searches let a mass spectrometry search engine match a peptide spectrum without the analyst specifying modifications in advance, but they commonly report only a single unexplained mass difference. When two or more modifications sit on the same peptide, that number alone does not say which modifications produced it. Buur and colleagues describe MS Andrea, a search engine that identifies and scores combinations of modifications at the level of each individual peptide-spectrum match. It uses a sequence-tag filter scored with the MS Amanda engine, together with modification combinations drawn from the Unimod database.
The tool was evaluated on a histone dataset and two phosphopeptide datasets (from HeLa cells and from Arabidopsis) and compared with the MSFragger and Sage search engines. The authors report that MS Andrea returned the most peptide-spectrum matches at a 1% false discovery rate and assigned modification identities and sites for up to four modifications on a single peptide.
What this does and does not establish. This is a computational and analytical study run on proteomics datasets of biologically derived peptides. It reports identification performance on those datasets at the stated error threshold; it does not evaluate synthetic-peptide quality control or serve as a validated release method, and its performance on other sample types would need independent benchmarking.
Source: Buur, L. M., et al. “Beyond Delta Masses: MS Andrea Directly Resolves Combinatorial Peptide Modifications in Open Searches.” Journal of Proteome Research, published online October 27, 2026. doi:10.1021/acs.jproteome.6c00296
Related guide: What Is Mass Spectrometry?
Helical peptide conjugates on gold: electron-transfer measurements in self-assembled monolayers
StudyRabah and colleagues report three conjugates that join a ferrocene unit, a BODIPY dye and a C60 fullerene to a helical peptide, assembled through successive copper-catalysed azide–alkyne cycloaddition (CuAAC, or “click”) reactions. The conjugates absorb broadly across the visible range. A terminal lipoyl group on the peptide allowed them to be grafted onto gold surfaces as self-assembled monolayers, which were characterised by polarisation-modulation infrared reflection-absorption spectroscopy (PM-IRRAS) and ultrafast electrochemistry.
The authors report that heterogeneous electron-transfer rate constants measured for the BODIPY or fullerene units were higher than in comparable conjugates lacking ferrocene. They attribute this to folding of the conjugates within the monolayer, which would shorten the distance between those units and the metal surface.
What this does and does not establish. This is a materials and electrochemistry study performed entirely on functionalised gold surfaces in vitro. It characterises three specific conjugates under the authors’ measurement conditions; the folding explanation is the authors’ proposed interpretation of the rate data rather than a direct structural observation reported in the abstract. No biological testing was involved.
Source: Rabah, J., et al. “Self-Assembled Monolayers on Gold Surfaces of Ferrocene-BODIPY-Fullerene-Helical Peptide Conjugates: Studies of Electron Transfer Processes by Ultra-Fast Electrochemistry.” Journal of Peptide Science, published online October 27, 2026. doi:10.1002/psc.70142
Related guide: What Is a Disulfide Bond? (the lipoyl anchor carries a cyclic disulfide)
All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This digest is educational and summarises published research and regulatory documents; it is not medical advice, does not describe how to use any product, and makes no therapeutic claim.